Latest News & Features
Americas
Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls. 17 June 2025
Careers
Ex-co-head of life sciences at previous firm brings expertise in multi-jurisdictional patent disputes involving supplementary protection certificates and second medical use claims. 17 June 2025
Europe
Government unveils £8M OpenBind consortium to lead in AI drug discovery | Project to build world’s largest drug–protein dataset | Backed by new Sovereign AI Unit, Consortium will be based at national synchrotron facility in Oxfordshire. 13 June 2025
Europe
Unified Patent Court announces new case management system this summer | Release will be in two phases, with first phase focusing on opt-out functionalities and representatives’ registration. 12 June 2025
Americas
Two decisions by acting USPTO director Coke Morgan Stewart have “damaging” consequences, warns Vidal | Stewart kickstarts campaign of implied criticism of predecessor’s record. 12 June 2025
Careers
Three seasoned lawyers with experience in biotech, pharmaceutical, and medical device patent matters join the firm's practice in Washington, DC and Chicago offices. 12 June 2025
Biotechnology
Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art. 12 June 2025
Americas
US appeals court confirms validity of Acadia's Nuplazid patents | Decision fends off generics from MSN Laboratories and Aurobindo Pharma until 2030s. 10 June 2025
Americas
Office’s acting director lifts severe penalties against patent owner following Federal Circuit remand | Issues separate decision highlighting consequences of “lengthy awareness” of patent portfolio. 10 June 2025
Americas
Biotech company convinces judges over claim construction interpretation | Alnylam “acted as lexicographer” regarding a claim term | Win comes as Moderna suffers economic challenges. 5 June 2025